Products

What will AGI do for Betacetylmethadol?

This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 905GLN509G, chemically known as 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3r,6r)-(-)- but generally known as betacetylmethadol, which bears US NIH Compound Identifier 62710. European Medicines Agency schedules Betacetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05792MIG. The term BETACETYLMETHADOL is an International Non-Proprietary Name. BETACETYLMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betacetylmethadol under HS 29221980 and SITC 51461. As of Q4 2014, BETACETYLMETHADOL remains the US FDA Preferred Term for this commodity. Betacetylmethadol bears US NLM identifiers UMLS ID C2698377 and NCI Concept Code C77278. SMILES: O(C(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC)C(=O)C.

How AGI delivers it

Four ways AGI delivers for Betacetylmethadol

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Betacetylmethadol, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Betacetylmethadol, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Betacetylmethadol connects

measured by

  • Assay Puritymodel
  • Chiral Enantiomeric Excessmodel
  • Melting Pointmodel